Estrogen-dependent activation of TRX2 reverses oxidative stress and metabolic dysfunction associated with steatotic disease
Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of hepatic disorders, ranging from simple steatosis to steatohepatitis, with the most severe outcomes including cirrhosis, liver failure, and hepatocellular carcinoma. Notably, MASLD prevalence is lower...
Saved in:
Main Authors: | Alfredo Smiriglia, Nicla Lorito, Marina Bacci, Angela Subbiani, Francesca Bonechi, Giuseppina Comito, Marta Anna Kowalik, Andrea Perra, Andrea Morandi |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2025-01-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-025-07331-7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Myrsini Orfanidou, et al.
Published: (2024-12-01) -
Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Jessica M. Rubino, et al.
Published: (2025-01-01) -
Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
by: Gong Feng, et al.
Published: (2025-03-01) -
Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
by: Melchor Alpízar Salazar, et al.
Published: (2025-01-01) -
Nicotinamide Adenine Dinucleotide Phosphate Oxidases and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Vittoria Cammisotto, et al.
Published: (2025-01-01)